James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
Location status: Recruiting
Location contact
Goetz H Kloecker, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT00682032
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Louisville, Kentucky, 40202, United States
Location status: Recruiting
Goetz H Kloecker, MD
PRINCIPAL_INVESTIGATOR
Beta-glucan (Imucell WGP) is an over-the-counter dietary supplement that enhances the body's immune system. Imucell WGP is extracted from food-grade baker's yeast, which is permitted for use in food by the U.S. Food and Drug Administration (FDA). Studies in animals have shown that Imucell WGP helps trigger white blood cells to destroy cancer cells. Other animal studies combining Imucell WGP with anti-cancer medications have shown greater tumor regression and tumor-free survival.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
AIM 2:
Inclusion criteria
Exclusion criteria
AIM 3:
Inclusion criteria
Exclusion criteria
AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
Other names: Imucell WGP
Time frame: pre-treatment and post-treatment
compare CR3 CBRM1/5 expression, CR3-dependent cellular cytotoxicity, myeloid-derived suppressor cells (MDSC) frequency, and T-cell function (cytokine secretion) before and after beta-glucan uptake
Time frame: post-treatment
AIM 3 only
Contact information is provided by the study sponsor or research team.
University of Louisville
Other
Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06540196
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hamilton, Ontario, Canada
View Trial DetailsNCT06694454
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bethesda, Maryland, United States
View Trial DetailsNCT04928846
Bronchial Neoplasms, Carcinoma, Bronchogenic
Birmingham, Alabama, United States
View Trial DetailsNCT06150664
Breast Diseases, Breast Neoplasms
Margate, Florida, United States
View Trial Details